Protagonist Therapeutics, Inc. (PTGX)

NASDAQ: PTGX · IEX Real-Time Price · USD
36.12
+0.33 (0.92%)
At close: Jul 12, 2024, 4:00 PM
37.39
+1.27 (3.52%)
After-hours: Jul 12, 2024, 7:19 PM EDT
0.92%
Market Cap 2.12B
Revenue (ttm) 314.95M
Net Income (ttm) 162.11M
Shares Out 58.65M
EPS (ttm) 2.52
PE Ratio 14.33
Forward PE 15.02
Dividend n/a
Ex-Dividend Date n/a
Volume 1,391,160
Open 36.26
Previous Close 35.79
Day's Range 35.64 - 36.86
52-Week Range 13.72 - 36.86
Beta 2.12
Analysts Strong Buy
Price Target 39.20 (+8.53%)
Earnings Date Aug 1, 2024

About PTGX

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an oral... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Aug 11, 2016
Employees 112
Stock Exchange NASDAQ
Ticker Symbol PTGX
Full Company Profile

Financial Performance

In 2023, PTGX's revenue was $60.00 million, an increase of 125.73% compared to the previous year's $26.58 million. Losses were -$78.96 million, -38.02% less than in 2022.

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for PTGX stock is "Strong Buy." The 12-month stock price forecast is $39.2, which is an increase of 8.53% from the latest price.

Price Target
$39.2
(8.53% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Protagonist Therapeutics to Participate in the Jefferies Global Healthcare Conference 2024

NEWARK, CA / ACCESSWIRE / May 31, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.

6 weeks ago - Accesswire

Protagonist Therapeutics Announces Oral Presentation on Long-Term Follow-up of Rusfertide Phase 2 REVIVE Study Open Label Extension at the European Hematology Association 2024 Congress

NEWARK, CA / ACCESSWIRE / May 14, 2024 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or the "Company") today announced that additional data from the rusfertide Phase 2 REVIVE open labe...

2 months ago - Accesswire

Protagonist Therapeutics to Participate in the Citizens JMP Life Sciences Conference and the Capital One 1st Annual Biotech/Biopharma Disruptors Event

NEWARK, CA / ACCESSWIRE / May 7, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") (NASDAQ:PTGX) today announced that Dinesh V. Patel, Ph.D.

2 months ago - Accesswire

Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update

Entered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027[1] Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials of JNJ-2...

2 months ago - Accesswire

Protagonist Therapeutics Provides Update on VERIFY Patient Enrollment and Timing of Top-line Data

On track to achieve 250 patient enrollment target in March 2024 Top-line data for 32-week primary endpoint expected in the first quarter of 2025 NEWARK, CA / ACCESSWIRE / March 26, 2024 / Protagonist ...

3 months ago - Accesswire

Protagonist Therapeutics Announces Closing of Worldwide Rusfertide License and Collaboration Agreement with Takeda

NEWARK, CA / ACCESSWIRE / March 18, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announces the closing of the worldwide collaboration and license agreement for rusferti...

4 months ago - Accesswire

Protagonist Therapeutics to Participate in Upcoming Investor Conferences

NEWARK, CA / ACCESSWIRE / March 6, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that they will participate in three upcoming investor conferences: Event: 2024...

4 months ago - Accesswire

Protagonist Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Worldwide collaboration agreement executed with Takeda Pharmaceuticals, including a $300 million upfront payment for rusfertide in polycythemia vera and other hematological indications Cash runway ext...

4 months ago - Accesswire

New England Journal of Medicine Publishes Results of Positive Randomized Phase 2 REVIVE Trial of Rusfertide in Treatment of Polycythemia Vera

- Trial met the primary efficacy endpoint achieving a clinically and statistically significant response in maintaining hematocrit control below 45% without phlebotomy - Rusfertide was associated with ...

5 months ago - Accesswire

Protagonist Therapeutics Reports Granting of Inducement Awards

NEWARK, CA / ACCESSWIRE / February 20, 2024 / Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on February 15, 2024, it issued inducement awards to Sid Reddy, the Company's recently hi...

5 months ago - Accesswire

New England Journal of Medicine Publishes Efficacy and Safety Data of Targeted Oral Peptide JNJ-2113 in a Phase 2b Moderate-To-Severe Plaque Psoriasis Study

JNJ-2113 achieved all primary and secondary endpoints in the Phase 2b clinical trial FRONTIER 1, including PASI 100 and IGA 0 responses of 40.5 percent and 45.2 percent, respectively. NEWARK, CA / ACC...

5 months ago - Accesswire

Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigatio...

Other symbols: TAK
5 months ago - Accesswire

Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

NEWARK, CA / ACCESSWIRE / January 29, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.

5 months ago - Accesswire

Protagonist Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

NEWARK, CA / ACCESSWIRE / January 3, 2024 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced that Dinesh V. Patel, Ph.D.

6 months ago - Accesswire

Protagonist Earns $10 Million Payment for Achievement of Clinical Milestone in Phase 2b ANTHEM-UC Study of JNJ-2113 in Adults with Moderately to Severely Active Ulcerative Colitis

NEWARK, CA / ACCESSWIRE / December 13, 2023 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") today announced it has earned a $10 million milestone payment following the dosing of the ...

7 months ago - Accesswire

Protagonist Therapeutics Ranked in the Top 3% of Fastest-Growing Companies in North America on the 2023 Deloitte Technology Fast 500(TM)

NEWARK, CA / ACCESSWIRE / November 9, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) today announced it ranked in the top 3% of the 2023 Deloitte Technology Fast 500TM , a list of the fastest-growing t...

8 months ago - Accesswire

Protagonist Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Five rusfertide abstracts accepted for oral and poster presentations at the 65th ASH Annual Meeting and Exposition (ASH2023) Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (fo...

9 months ago - Accesswire

Protagonist Therapeutics Announces Abstracts Selected for Oral and Poster Presentations at the American Society of Hematology 2023 Annual Meeting

Two oral presentations and three poster presentations elucidate new data relevant to rusfertide, a hepcidin mimetic with potential therapeutic value in the treatment of Polycythemia Vera and other dis...

9 months ago - Accesswire

Protagonist Therapeutics Announces Appointment of Daniel Swisher to Its Board of Directors

NEWARK, CA / ACCESSWIRE / October 30, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced the appointment of Daniel N. Swisher, Jr. to its Board of Directors...

9 months ago - Accesswire

Protagonist Announces Advancement of JNJ-2113 Across Multiple Indications

ICONIC Phase 3 clinical program initiation in adults with moderate to severe plaque psoriasis ANTHEM Phase 2b initiation in ulcerative colitis Company is eligible to receive next two milestone payment...

9 months ago - Accesswire

Protagonist Therapeutics Reports Granting of Inducement Award

NEWARK, CA / ACCESSWIRE / October 3, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) today reported that on September 29, 2023, it issued inducement awards to Katharina Modelska, M.D., Ph.D., the ...

10 months ago - Accesswire

Protagonist Therapeutics to Present at Upcoming Investor Conferences

NEWARK, CA / ACCESSWIRE / September 5, 2023 / Protagonist Therapeutics, Inc. (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced that Dinesh V. Patel, Ph.D.

11 months ago - Accesswire

Protagonist Receives $34 Million from Warrant Exercises

Estimated cash runway now extended through Q1 2026 NEWARK, CA / ACCESSWIRE / August 9, 2023 / Protagonist Therapeutics (NASDAQ:PTGX) ("Protagonist" or "the Company") today announced it has received ap...

1 year ago - Accesswire

Protagonist Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Positive topline results from the Phase 2b FRONTIER 1 study of JNJ-2113 (formerly PN-235), the first and only IL-23 receptor antagonist oral peptide drug candidate for the treatment of moderate-to-sev...

1 year ago - Accesswire

Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Quarter

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Other symbols: BCLICOSMSHCRXAIR
1 year ago - Benzinga